Every now and then, we see retraction notices that refer vaguely to legal issues. Sometimes, we can dig up the actual reason. But the European Biophysics Journal has two retractions that leave us completely in the dark.
The two notices basically say the same thing. Here’s one: Continue reading “Unsolved legal reasons” cause retraction of two biophysics papers
A bit of intellectual property indiscretion has led to the retraction of a paper by Korean scientists. Although the details are fuzzy, several of the authors are affiliated with a Korean pharma company called SK.
The paper, “A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons,” was published in the The Korean Journal of Physiology & Pharmacology earlier this year.
According to the retraction notice: Continue reading Loose lips sink paper on company’s experimental pain drug
The editors of the World Journal of Emergency Surgery have published an Expression of Concern about a paper after they couldn’t verify one of the three case reports in it.
Here’s the notice for “Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and management with three case reports: torso, abdominal wall, upper and lower limbs,” by surgeons from Split and Zagreb, Croatia: Continue reading Surgery journal issues Expression of Concern when institution can’t confirm case study details “for legal reasons”
Irony alert: The Journal of Forensic and Legal Medicine, which really ought to know better, is retracting a 2012 article by an Australian researcher that threatened to run afoul of…privacy law.
The article, “A challenging injury interpretation: Could this be a stab wound?” was written by Les Griffiths, of the Clinical Forensic Medical Unit at University of Queensland in Brisbane. According to the notice: Continue reading Legal medicine journal pulls paper over image goof
Acta Anaesthesiologica Scandinavica has retracted a 2008 paper by a group of Estonian researchers who appear to have wound up in legal jeopardy for misrepresenting their work.
Here’s the notice: Continue reading Anesthesia journal retracts paper from Estonian researchers in wake of legal inquiry
The authors of a paper on websites that sell cholesterol-lowering statin medications without prescriptions have retracted it. The move followed the threat of a lawsuit against the journal by a company included in the study that says it never dispenses sans a script.
Here’s the notice: Continue reading Statins without prescription website paper retracted after company says it requires scripts, threatens suit
A group of researchers at the drug company ChemoCentryx is withdrawing a 2012 paper in the Journal of Pharmacology and Experimental Therapeutics over failure to appropriately identify the molecule they describe in the article.
The withdrawal notice tells the story: Continue reading JPET peeves: Paper withdrawn after drug company won’t disclose chemical structure
When we broke the story last week about a juicy retraction notice in the American Journal of Obstetrics & Gynecology (AJOG) — known by its readers as “the Gray Journal” — we wrote that there was more to it than we suspected. That’s an understatement.
As we reported, the AJOG retracted an article that it had published earlier this year because 1) the author, Laurence Cole, had failed to disclose a potential financial conflict of interest with a pregnancy test maker named Church & Dwight; and 2) the article lacked a “credible scientific reason given for conducting the study,” along with other flaws detailed in the notice. (As we wrote the other day, we wonder why those issues did not arise during the initial review of the manuscript — but more on that shortly.)
We’ve since learned that the journal’s move came after it received a sharply worded letter from a high-powered San Francisco lawyer demanding immediate retraction of the article on the grounds that it represented a “substantial” threat to the financial health of his client. That client? A maker of home pregnancy tests who is now in the process of suing the very firm that provided Cole with research funding he failed to disclose.
First, here’s what Cole, the hormone expert at the University of New Mexico whose paper the journal retracted, said about why he didn’t disclose that funding: Continue reading Elsevier ob-gyn journal retracted paper after legal threat
Two chemists who published a paper earlier this year in Bioconjugate Chemistry have withdrawn it, after their company, Life Technologies, let them know they didn’t have permission to submit the work. The retraction notice reads:
Facile Synthesis of Symmetric, Monofunctional Cyanine Dyes for Imaging Applications, by Lai-Qiang Ying and Bruce P. Branchaud, Bioconjugate Chem., 2011, 22 (5), pp 865–869, DOI: 10.1021/bc2001006, has been retracted at the request of the authors and Life Technologies. The article was submitted for publication without the approval of Life Technologies.
Where the paper had appeared previously — it’s been completely removed from the journal’s site, as opposed to being marked as “withdrawn” or “retracted” — this is all that’s left: Continue reading Authors retract chemistry paper after failing to get company’s permission to publish
Readers of this blog by now know that if there’s one thing that really gets us going, it’s obfuscation. So it shouldn’t be surprising that the following retraction notice from the journal Psychopharmacology, made us particularly batty:
This paper has been retracted by the author because of legal issues.
The notice refers to “Selective activation of the metabotropic glutamate receptor subtype 7 “mGluR7” attenuates acquisition, expression, and reinstatement of ethanol place preference,” was published online in late June by Amine Bahi under the heading “Original Investigation.”
Bahi is in the department of anatomy at United Arab Emirates University. He has also held positions at Yale and the University of Fribourg in Switzerland. Among his publications is one that involved a collaborator from Novartis (more on that in a moment). Continue reading Cryptic “legal issues” lead to retraction of paper about potential Novartis alcohol abuse drug